The interagency strategic plan for research and development of blood products and related technologies for trauma care and emergency preparedness 2015-2020

• DOI: 10.5055/ajdm.2018.0299
• Publication Date: 2019-01-31T19:14:32Z
• Authors: Anthony E. Pusate...; Mary J. Homer, PhD; Todd E. Rasmussen...; Kevin R. Kupferer...; W. Keith Hoots, MD
• Keywords: Preparedness

Intensive blood use is expected to occur at levels, which will overwhelm supplies as they exist with current capabilities and technologies, both in civilian mass casualty events military battlefield trauma. New technologies are needed for trauma care, specifically provide safer, more effective, logistically supportable products treat patients with, or risk of developing, acquired bleeding disorders resulting from trauma, acute radiation exposure, other causes. Three the primary agencies major research development programs related products, Biomedical Advanced Research Development Authority (BARDA), Department Defense (DoD), National Heart, Lung, Blood Institute uniquely positioned partner addressing these issues, have significant implications each respective agency, well US population. Providing leadership, coordination, oversight Food Drug Administration’s national global health security, counterterrorism, emerging threats portfolios, Administration Office Counterterrorism Emerging Threats serves a critical advisory facilitative role regarding availability products. This plan informed by 2012 PHEMCE Strategy (US Health Human Services, 2012), 2007 “Shaping Future Research” Strategic Plan Institute, 2011 BARDA Plan, DoD Combat Casualty Care Program: Policy Review, 2015 Hemorrhage Resuscitation than 30 participants who participated planning.